Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adavosertib in Japanese Patients With Advanced Solid Tumours
NCT04462952Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Jun 2020
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of adavosertib in solid tumor (advanced stage) (2 arms), sponsored by AstraZeneca. Primary endpoints: Incidence of Adverse events and Incidence of Dose-limiting toxicity. Started Jun 2020; status: completed.
02
Drugs
adavosertib
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT04462952.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04462952.